Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Home

Header Top Menu

  • News & Featured Stories
  • Media
  • Careers
  • Contact Us
  • Our Science

    Sub Menu 1

    • Pfizer in the UK
      • Our History
      • Pharmaceutical Sciences
      • Devices Centre of Excellence
      • Global Regulatory Affairs
      • Material Characterisation Team
      • Anti-Counterfeit Laboratory
    • Our Therapy Areas
      • Anti-Infectives
      • Inflammation and Immunology
      • Internal Medicine
      • Oncology
      • Rare Disease
      • Vaccines

    Sub Menu 2

    • Developing New Medicines
      • Clinical Trials
      • Pipeline
    • Research partnerships
      • ADDoPT
      • Innovative Target Exploration Network (ITEN)
      • INSPIRE Programme
      • Medical Research Council Collaboration
      • The Stratified Medicine Programme
      • Partnership with Regeneron for UK Biobank exome sequencing
    • Breakthroughs that change patients’ lives
    Hot Topic

    Re-shaping Cancer

    Re-shaping cancer
  • Products

    Sub Menu 4

    • Prescription medicines

    Sub Menu 5

    • Safety of Medicines
      • Medicines Regulation
      • Reporting Side Effects
      • Counterfeit Medicines
    Hot Topic

    Vaccines partnerships

    Vaccines partnerships
  • Responsibility

    Sub Menu 7

    • Transparency
      • HCP & HCO Annual Disclosure Reports
      • Healthcare Organisation Grants
      • Research and Development Funding
      • Patient Organisation Funding and Support
    • Codes of Conduct
      • Gender Pay Gap Report
      • Section 172 Statements
      • Pfizer UK Modern Slavery Statement
      • Pfizer UK Tax Strategy

    Sub Menu 8

    • Environmental Sustainability
      • Climate Action
      • Global Actions
      • Our Partnerships & Commitments
      • Sustainable Medicines
      • UK Actions
    • Insurance Details
    • Animal Welfare
    Hot Topic

    Putting Patients First

    Putting Patients First
  • UK Society

    Sub Menu 10

    • Social Investment
      • Volunteering and Fundraising
      • Medicines Donations
    • Raising Public Awareness
      • Change the Course
      • Pfizer Sponsors Science Museum Group's 'Cancer Revolution' Exhibition
      • Pfizer Sponsors the Superhero Series
      • Pfizer sponsors Science Museum exhibition 'Superbugs'
      • Pfizer at the British Science Festival
      • Turning Heads at Westminster

    Sub Menu 11

    • Science Education
      • Developing Science Talent
      • 'Superbugs Join The Fight' School Programme
      • Online Learning
        • Student Education Area
        • Teacher Resources
      • Community Lab
      • Career Talks
      • Lab in a Box
    • Pfizer Worldwide
      • Global Health Fellows
      • Global Aid and Emergency Relief
      • International Trachoma Initiative
    Hot Topic

    'Superbugs' Competition Winners

    Superbugs Winners
  • UK Health System

    Sub Menu 16

    • Working with the NHS and other Healthcare Organisations
      • Collaborative Working
        • Collaborative Working Project between Lloyds Pharmacy and Pfizer Vaccines
        • Joint Working
      • Donations and Grants
        • Independent Medical Grants and Donations
        • Donations of Goods, Services and Benefit in Kind
        • Grants
        • Donations and Grants Enquiry Form
    • Working with Healthcare Professionals
      • FAQs: Working with Healthcare Professionals
      • Pharmacy
      • Healthcare Professionals Congress Sponsorship

    Sub Menu 17

    • Working with Patient Organisations
      • Patient Involvement in Research and Development
      • Our ongoing partnership with the UK Sepsis Trust
      • Partnering with the NIHR and young people on clinical research
    • Pfizer Healthcare Hub
      • Pfizer Healthcare Hub: 2018
      • Pfizer Healthcare Hub: 2017
      • Connect with the Hub
    Hot topic

    Osteoarthritis

    Osteoarthritis
  • News & Featured Stories
  • Media
  • Careers

    Carrers

    • Search Current Vacancies
    • Apprenticeships
      • Apprenticeship Vacancies
    • Undergraduate Placements
      • Undergraduate Vacancies
    • Meet our people
    • UK Top Employer
    • How Pfizer is fostering meaningful growth for every colleague, everywhere
  • Contact Us
  • Footer links

    Footer mobile menu

    • Footer Menu
    • Footer menu
      • Contact Us
      • Cookie Policy
      • Terms of Use
      • Privacy Policy
      • Sitemap
    • Footer social item
      • Facebook
      • Twitter
      • Instagram
      • YouTube

Knowledge is power: empowering breast cancer patients with joint decision-making

Knowledge is power: empowering breast cancer patients with joint decision-making
News & Featured Stories/ Knowledge is power: empowering breast cancer patients with joint decision-making
27/10/2020

Erling Donnelly
Head of Oncology, Pfizer UK

The effect of breast cancer ripples across society, far beyond the individual receiving the diagnosis.

 

As the most common cancer in the UK, it impacts over 46,000 women and men each year, affecting their career, self-confidence and mental health.1,2 However, it also has a significant impact on family members who make extra trips to hospital, friends who provide much-needed emotional support, and spouses who find themselves as the sole source of income. No two people are the same, and, as such their priorities for cancer treatment should be based on individual circumstances. As the NHS Long Term Plan recognises, ‘what is the matter with someone’ is not always the same as ‘what matters to someone’.3 With this in mind, patients should be empowered to work closely with clinicians and provide input on which treatment will best suit their circumstances and lifestyles.  

Supporting individual cancer journeys

Earlier this year, Pfizer commissioned the think-tank Demos to quantify the ‘ripple effect’ of cancer and examine the social and economic impact of a diagnosis. The results were stark. The Cancer Costs report found that 48 per cent of cancer patients had to make structural changes to their working patterns because of illness.4 Women are particularly affected, with 55 per cent changing their working habits compared to just 40 per cent of men.4 It is clear that people require a holistic package of support that is tailored to their specific needs and circumstances. Some patients may prioritise continuing their career, whilst others may wish to fit treatment around childcare duties.

As a consequence of the COVID-19 pandemic, the NHS has implemented rapid guidance to enable greater flexibility in the delivery of cancer treatment.5 In order to ease the burden on hospitals and staff, some people with cancer have had access to repeat prescriptions, at-home treatments and the use of oral medicines where possible.5 Whilst these changes are certainly welcome, the impact of COVID-19 has restricted patients’ access to healthcare if they notice symptoms.6 This has led to a significant reduction in diagnosis and – for those with cancer – access to treatment.7 In fact, Cancer Research UK estimates that more than two million people in the UK are now waiting for screening, tests and treatment.8 This means that patients are less actively involved in their care plans. However, if patients are regarded as equal partners in decision-making, health outcomes are improved, quality of life is enhanced and services can be delivered more appropriately and cost-effectively.9 Therefore, as the NHS prepares its post-COVID recovery plans, it will be fundamental that patient choice and truly shared decision-making is prioritised from the beginning of a patient’s cancer journey.

Ultimately, decisions around care should reflect individual circumstances. To this end, it is important that prescribing decisions are made in consultation with the patient and are driven by their personal characteristics and circumstances." 

Knowledge is power

As the saying goes ‘knowledge is power’, and this certainly rings true when facing a cancer diagnosis. At Pfizer, we believe it is vital that patients are empowered to jointly make informed decisions about their care. Part of being informed involves understanding their diagnosis and the treatment options, but it is not easy. According to a recent National Cancer Patient Experience Survey, just 77% of breast cancer patients ‘completely understood’ their diagnosis.10

One way that Pfizer is helping to provide clear information to patients is through our new ‘What’s Breast for Me’ initiative. Our aim is to educate people on secondary breast cancer and empower them to communicate their treatment goals with their doctor. We know, thanks to Breast Cancer Now’s chief executive Baroness Delyth Morgan, that people with secondary breast cancer may have a poorer experience of care than those diagnosed with primary breast cancer,  so a crucial element of the campaign is to encourage patients to speak to their doctor about what is important to them following a diagnosis. Whether this involves ensuring they can attend an important upcoming event or keeping active, we understand that providing tailored support can make a significant difference to a patient’s mental health.11

Ultimately, decisions around care should reflect individual circumstances. To this end, it is important that prescribing decisions are made in consultation with the patient and are driven by their personal characteristics and circumstances. While it is near impossible to quantify the impact of COVID-19 on cancer care across the UK, we must continue to work towards greater patient empowerment in spite of these challenges. Putting the individual at the heart of their own cancer journey is essential to helping people continue to live fulfilling lives with, and beyond, cancer.

 

References

  1. Office for National Statistics. Cancer registration statistics, England: 2017 April 2019.
  2. The National Center for Biotechnology Information. Self-confidence and quality of life in women undergoing treatment for breast cancer, Asian Pacific Journal of Cancer Prevention 2018
  3. NHS. The NHS Long Term Plan, January 2019.
  4. Demos. Cancer Costs: A Ripple Effect Analysis of Cancer’s Wider Impact January 2020.
  5. NICE. COVID-19 rapid guideline: delivery of systemic anticancer treatments April 2020
  6. The Lancet. COVID-19: impact on cancer workforce and delivery of care April 2020 
  7. The Lancet. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study July 2020
  8. Cancer Research UK. Over 2 million people waiting for cancer screening, tests and treatment June 2020
  9. The National Center for Biotechnology Information. Patient involvement in health care decision making: A review, Iranian Red Crescent Medical Journal January 2014
  10. National Cancer Patient Experience Survey. 2019 national level breakdowns
  11. Breast Cancer Now. Breast Cancer Now comments on the National Cancer Patient Experience Survey 2016 results. Data on file.

 

PP-PFE-GBR-4220 / November 2021

Related Hot Topics
AMR Reimbursement Pilot Launch
World First Cross-Industry Initiative Launches in the Continued Fight Against…
VacciNation report
VacciNation: tackling health inequalities across England
Patients at heart of clinical trials
Why putting patients at the heart of Pfizer UK’s clinical trials continues to…
Infection Management Coalition Paper
Cross-Industry Coalition Tackling ‘Hidden Pandemic’ of Antibiotic Resistant…
Blueprint for gene therapy adoption
Pfizer UK launch blueprint for the UK adoption of cell and gene therapies
Inhealthcare
Inhealthcare: where are they now?
Re-shaping cancer
Re-shaping Cancer - Breakthroughs that change patients' lives
Osteoarthritis
Osteoarthritis: It’s time to talk about mental health
Tags
UK Health System
Oncology

Footer

  • Contact Us
  • Cookie Policy
  • Terms of Use
  • Privacy Policy
  • Sitemap

Footer aside

  • Footer Aside
    • Facebook
    • Twitter
    • Instagram
    • YouTube

Copyright © 2017-2022 Pfizer Limited. PP-PFE-GBR-4248 / Nov 2021. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427